MedTrace Logo

A Study of Nivolumab and Chemotherapy Followed by Surgery for Mesothelioma

NCT04162015 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 22

Last updated 2025-09-12

No results posted yet for this study

Summary

This study will test whether giving nivolumab in combination with pemetrexed and either cisplatin or carboplatin before surgery is a safe and effective approach to treating resectable mesothelioma without delaying surgery.

Conditions

  • Malignant Pleural Mesothelioma

Interventions

DRUG

Nivolumab

nivolumab 360 mg

DRUG

Pemetrexed

500 mg/m\^2

DRUG

Cisplatin or Carboplatin

cisplatin 75 mg/m2 or carboplatin AUC=5

Sponsors & Collaborators

Principal Investigators

  • Michael Offin, MD · Memorial Sloan Kettering Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-11-12
Primary Completion
2026-11-30
Completion
2026-11-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04162015 on ClinicalTrials.gov